表紙:血液がん治療薬の世界市場 (2027年まで) - 上市製品・パイプライン製品、機会、課題、市場規模、主要企業
市場調査レポート
商品コード
1023478

血液がん治療薬の世界市場 (2027年まで) - 上市製品・パイプライン製品、機会、課題、市場規模、主要企業

Global Hematological Cancer (Blood Cancer) Therapy Market to 2027 - Comprehensive Overview of Marketed and Pipeline Products, Opportunities, Challenges, Market Size and Key Players

出版日: | 発行: GlobalData | ページ情報: 英文 125 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.72円
血液がん治療薬の世界市場 (2027年まで) - 上市製品・パイプライン製品、機会、課題、市場規模、主要企業
出版日: 2021年08月31日
発行: GlobalData
ページ情報: 英文 125 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

主な成長要因としては、幅広い治療法を網羅する複数のパイプライン療法の承認と発売が予想されることが挙げられますが、中でも細胞治療は、2027年までに最も大きな成長を遂げると予想されています。現在、売上に占める割合が最も高いのは標的療法で、次いで抗体です。2016年以降、これらの治療薬を合わせると、売上の90%以上を占めています。適応症固有の違いにより、複数の治療法にアクセスできる患者がいる一方で、十分な治療を受けられない患者もいます。パイプラインのイノベーションの度合いは、適応症によって大きく異なります。

当レポートでは、世界の血液がん治療薬市場について調査分析し、主要動向、臨床試験、上市製品・パイプライン製品、市場分析と予測、アンメットニーズ、主要企業などについて、体系的な情報を提供しています。

目次

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 血液がんの概要

  • 血液がんとは
  • 血液がんの治療管理
  • 主要8ヶ国における血液がん治療の重要なマイルストーン

第4章 動向

  • 業界動向

第5章 バリューチェーン

  • 血液がんのバリューチェーン
  • 抗体
  • 細胞治療
  • 化学療法
  • その他のMOA
  • 標的療法

第6章 臨床試験

  • 血液がんの臨床試験
  • 血液がんの進行中の臨床試験
  • 血液がんの進行中の臨床試験:地域別
  • 血液がんの進行中の臨床試験:主要スポンサー別
  • 血液がんの臨床試験:課題
  • 血液がんの臨床試験:機会

第7章 上市製品

  • 世界の上市済み血液がん製品
  • 主要8ヶ国における上市済み血液がん製品
  • 血液がんの総市場規模
  • 世界の主要な抗体治療
  • 世界の主要な細胞治療
  • 世界の主要な化学療法治療
  • 世界の主要なその他のMOA治療
  • 世界の主要な標的療法治療

第8章 パイプライン製品

  • 世界の血液がんパイプライン製品
  • 世界の血液がんパイプライン:抗体
  • 世界の血液がんパイプライン:細胞治療
  • 世界の血液がんパイプライン:化学療法
  • 世界の血液がんパイプライン:その他のMOA
  • 世界の血液がんパイプライン:標的療法

第9章 市場分析

  • 市場分析と予測:抗体
  • 市場分析と予測:細胞治療
  • 市場分析と予測:化学療法
  • 市場分析と予測:その他のMOA
  • 市場分析と予測:標的療法
  • 2017年以降に血液がん分野で完了した取引トップ10
  • 血液がん分野の最新の取引
  • M&A:血液がん (2020年下半期~2021年上半期)
  • M&A:血液がん (2020年下半期)

第10章 企業

  • BMS
  • Johnson & Johnson/Janssen
  • Novartis
  • Pfizer
  • Roche

第11章 機会とアンメットニーズ

  • 世界の血液がん:機会
  • 世界の血液がん:課題
  • 血液がんにおけるアンメットニーズ:ギャップ分析

第12章 付録

目次
Product Code: GDHCHT287

Hematological cancers, often referred to as blood cancers, encompass over 100 diverse neoplasms that arise from the abnormal proliferation or differentiation of cells of the blood, bone marrow, or lymph nodes. Hematological cancers accounted for almost 10% of new cancer diagnoses in the US in 2020. A diverse array of drugs are used in the treatment of hematological cancers. Historically, chemotherapies were an important part of the treatment paradigm for many indications. The emergence of more targeted therapies in recent years has seen a shift away from chemotherapy, in some cases towards a more personalized approach. The use of cell therapies has been pioneered in the treatment of hematological cancers and several such therapies are now available for multiple indications.

The hematological cancer therapy market is diverse and highly genericized. Targeted therapies are currently the most valuable segment within the hematological cancer market, accounting for $39.9B worth of sales in 2020. Use of generic chemotherapies is expected to fall in the near future, while the use of targeted, personalized therapies is expected to increase.

Key Highlights

  • The main drivers of growth include the anticipated approval and launch of multiple pipeline therapies encompassing a wide range of therapeutic modalities, with cell therapies expected to see the greatest increase in growth to 2027.
  • Targeted therapies currently account for the highest proportion of sales, followed by antibodies. Together, these therapeutics have accounted for over 90% of sales since 2016.
  • Indication-specific differences means some patients have access to multiple therapy types, while others are underserved. The degree of pipeline innovation is highly variable between indications.
  • The most important unmet needs in the hematological cancer market include: the need for greater therapeutic options for relapsed/refractory patients across multiple indications, the need to better understand the most effective sequencing of treatments, the need for greater therapeutic options for high-risk patients and the need to reduce the increasingly high cost of therapy.

Key Questions Answered

  • What are the main trends in the treatment of hematological cancers today?
  • What is the status of clinical trials in hematological cancers? Which indications have the greatest number of late-stage trials and who are the most active sponsors of clinical trials in hematological cancers?
  • How does the market in branded therapies look in terms of therapy types? Which indications have the greatest number of marketed products? What are the top selling treatments globally?
  • How many and what types of therapies are currently in development? Which targets are most heavily investigated? Which indications have strong pipelines and which are lacking in diversity?
  • What are the current unmet needs across hematological cancers? What the opportunities for developers in this setting and what are the main challenges?

Scope

  • Overview of hematological cancers including classification and treatment management, and important milestones in the treatment of hematological cancers in the 8MM.
  • Global trends in the hematological cancer market, including the impact of cell therapies on the market and how their use is expected to evolve, and how the increased understanding of the molecular basis of disease is influencing treatment, diagnosis and prognosis across different hematological cancer indications.
  • Key topics covered include ongoing clinical trials, top selling agents from each treatment type, pipeline therapies, market analysis by treatment type, overview of noteworthy deals, and unmet needs and opportunities.
  • Pipeline analysis: Overview of pipeline products globally and in the 8MM, including breakdown by treatment type and split across different phases, analysis of highly investigated targets, overview of pipeline products by indication, phase and treatment type.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global hematological cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hematological cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global hematological cancer therapeutics market from 2020-2027.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1. Preface

  • 1.1. Table of Contents
  • 1.2. Abbreviations
  • 1.3. Related Reports

2. Executive Summary

  • 2.1. Key Findings

3. Hematological Cancer Overview

  • 3.1. What Are Hematological Cancers?
  • 3.2. Treatment Management for Hematological Cancers
  • 3.3. Important Milestones in the Treatment of Hematological Cancers in the 8MM

4. Trends

  • 4.1. Industry Trends

5. Value Chain

  • 5.1. Hematological Cancers Value Chain
  • 5.2. Antibodies
  • 5.3. Cell Therapies
  • 5.4. Chemotherapies
  • 5.5. Other MOAs
  • 5.6. Targeted Therapies

6. Clinical Trials

  • 6.1. Clinical Trials for Hematological Cancers
  • 6.2. Ongoing Clinical Trials for Hematological Cancers
  • 6.3. Ongoing Clinical Trials for Hematological Cancers by Region
  • 6.4. Ongoing Clinical Trials in Hematological Cancers by Leading Sponsors
  • 6.5. Clinical Trials in Hematological Cancers - Challenges
  • 6.6. Clinical Trials in Hematological Cancers - Opportunities

7. Marketed Products

  • 7.1. Hematological Cancers Marketed Products Globally
  • 7.2. Hematological Cancers Marketed Products in the 8MM
  • 7.3. Total Market Size for Hematological Cancers
  • 7.4. Leading Antibody Treatments Globally
  • 7.5. Leading Cell Therapy Treatments Globally
  • 7.6. Leading Chemotherapy Treatments Globally
  • 7.7. Leading Treatments with Other MOAs Globally
  • 7.8. Leading Targeted Therapy Treatments Globally

8. Pipeline Products

  • 8.1. Global Hematological Cancer Pipeline Products
  • 8.2. Global Hematological Cancer Pipeline - Antibodies
  • 8.3. Global Hematological Cancer Pipeline - Cell Therapies
  • 8.4. Global Hematological Cancer Pipeline - Chemotherapies
  • 8.5. Global Hematological Cancer Pipeline - Other MOAs
  • 8.6. Global Hematological Cancer Pipeline - Targeted Therapies

9. Market Analysis

  • 9.1. Market Analysis and Forecast - Antibodies
  • 9.2. Market Analysis and Forecast - Cell Therapies
  • 9.3. Market Analysis and Forecast - Chemotherapies
  • 9.4. Market Analysis and Forecast - Other MOAs
  • 9.5. Market Analysis and Forecast - Targeted Therapies
  • 9.6. Top 10 Completed Deals in the Hematological Cancer Space Since 2017
  • 9.7. Latest Deals in the Hematological Cancer Space
  • 9.8. Mergers and Acquisitions Hematological Cancer - H2 2020-H1 2021
  • 9.9. Mergers and Acquisitions Hematological Cancer - H2 2020

10. Companies

  • 10.1. BMS
  • 10.2. Johnson & Johnson/Janssen
  • 10.3. Novartis
  • 10.4. Pfizer
  • 10.5. Roche

11. Opportunities and Unmet Needs

  • 11.1. Global Hematological Cancers - Opportunities
  • 11.2. Global Hematological Cancers - Challenges
  • 11.3. Unmet Needs in Hematological Cancers - Gap Analysis

12. Appendix

  • 12.1. Bibliography
  • 12.2. Primary Research
  • 12.3. About the Authors
  • 12.4. About GlobalData
  • 12.5. Contact Us
  • 12.6. Disclaimer